Briggs W. Morrison, M.D.

Briggs W. Morrison, M.D., has served as a member of our board of directors since July 2015.

He previously served as our President, Head of Research and Development from February 2022 to April 2023 and Chief Executive Officer from June 2015 to January 2022. Dr. Morrison currently serves as Chief Executive Officer of Crossbow Therapeutics, as well as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, from 2007 to January 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison currently serves on the board of Arvinas, Carisma Therapeutics, Repare Therapeutics and Werewolf Therapeutics, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Codiak Biosciences, Oncorus and NextCure Therapeutics.

Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.